Compare MOMO & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOMO | GERN |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | China | United States |
| Employees | N/A | 229 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 926.4M | 1.1B |
| IPO Year | 2014 | N/A |
| Metric | MOMO | GERN |
|---|---|---|
| Price | $6.13 | $1.24 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.17 |
| AVG Volume (30 Days) | 399.8K | ★ 15.7M |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $3.68 | $43.75 |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.69 | $1.04 |
| 52 Week High | $9.22 | $2.01 |
| Indicator | MOMO | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 30.88 |
| Support Level | $5.69 | $1.24 |
| Resistance Level | $6.52 | $1.29 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 21.05 | 4.04 |
Hello Group Inc is a foremost player in Asia's online social networking space. Through Momo, Tantan and other properties within its product portfolio, It enable users to discover new relationships, expand their social connections and build meaningful interactions. Momo is a mobile application that connects people and facilitates social interactions based on location, interests and a variety of online recreational activities. Tantan, which it added to its family of applications through acquisition. Tantan is designed to help its users find and establish romantic connections as well as meet interesting people. The Group determined that it operated in three operating segments namely Momo, Tantan and QOOL. The majority of revenue comes from Chinese mainland as compare to Overseas.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.